Clinical trials: Epirubicin
Non-Hodgkin's Lymphoma
A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers
AIMS OF THE STUDY 1. To test if steroid-free chemotherapeutic regimens decrease the risk of HBV reactivation and hepatitis development in HBsAg (+) carriers. 2.
- Trial name
- NCT00262210
- Testing
- Cyclophosphamide Epirubicin Etoposide Prednisolone
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Marginal Zone Lymphoma
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients…
- Trial name
- NCT04433156
- Testing
- Bortezomib, Rituximab, Epirubicin
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC
The purpose of this study is to evaluate the efficacy and tolerability of the combination of epirubicin, oxaliplatin and 5-day continuous infusional 5-fluorouracil (EOF5 regimen) in patients with unresectable advanced or…
- Trial name
- NCT00767377
- Testing
- EOF5
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Fudan University
Breast Cancer
Study of Nab-Paclitaxel in High Risk Early Breast Cancer
two-armed trial to compare E-nP-C against tailored dtEC-dtD in patients with high risk early breast cancer
- Trial name
- GAIN-2 (NCT01690702)
- Testing
- Epirubicin, nab-Paclitaxel, Cyclophosphamide
- Where
- Germany
- Volunteers
- 2,886 people
- Sponsor
- GBG Forschungs GmbH
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids
Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial.
- Conditions
- Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade
- Trial name
- POLO (NCT06227065)
- Testing
- Epirubicin, Mitomycin, Gemcitabine
- Where
- 2 sites in Switzerland
- Volunteers
- 28 people
- Sponsor
- Hospital Centre Biel/Bienne
Breast Cancer
Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer
Patients with ER+/HER2- breast cancer (presumably the luminal A subtype) could potentially avoid the standard chemotherapy use. Letrozole Plus Low-Dose Metronomic Capecitabine may offer similar efficacy and less toxicity to…
- Trial name
- NCT03507465
- Testing
- Letrozole Plus Low-Dose Metronomic Capecitabine, EC-T
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Guangdong Provincial People's Hospital
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
This clinical study was designed to demonstrate that a single, intravenous dose of palonosetron 0.25 mg was not inferior to granisetron 3 mg in preventing acute and delayed CINV and was also well tolerated in the Chinese cancer…
- Trial name
- NCT00666783
- Testing
- palonosetron, Granisetron
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Xijing Hospital
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the…
- Conditions
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma
- Trial name
- FAST (NCT01630083)
- Testing
- epirubicin, oxaliplatin, capecitabine
- Where
- 48 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 252 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Nasopharyngeal Carcinoma (NPC)
Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy
Clinicopathological and genomic data (Next generation sequencing and IHC/CISH) in available tissues were performed in patients with nasopharyngeal carcinoma who participated in a previously conducted randomized phase II study…
- Trial name
- NCT07741110
- Testing
- Next generation sequencing, Immunohistochemistry/CISH
- Volunteers
- 141 people
- Sponsor
- Hellenic Cooperative Oncology Group
TNBC, Adjuvant Therapy
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
This study is a prospective, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of postoperative chemotherapy combined with QL1706 in patients with high-risk triple-negative breast cancer.
- Conditions
- TNBC, Adjuvant Therapy, Lymph Node Positive
- Trial name
- NCT07622836
- Testing
- Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B Cell Lymphoma, CD79A Gene Mutation
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of zanubrutinib combined with standard chemotherapy in the treatment for patients with diffuse large B cell lymphoma and…
- Conditions
- Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation
- Trial name
- NCT04668365
- Testing
- Rituximab, Zanubrutinib, Cyclophosphamide
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004237
- Testing
- cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- United Kingdom
- Sponsor
- Royal Marsden NHS Foundation Trust
Hepatocellular Carcinoma
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis
The purpose of this study is to investigate safety and potential therapeutic benefits for patients with hepatocellular carcinoma by transcatheter chemoembolization with the recombinant endostatin (commercially available in…
- Trial name
- TACE HCC (NCT00518557)
- Testing
- Transcatheter Arterial Chemoembolization
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Southeast University, China
Breast Cancer
Outcome of Neo-adjuvant Chemotherapy Followed by Breast Conservative Surgery in Breast Cancer in Upper Egypt
Systemic chemotherapy along with radiotherapy has been successfully used to post-operatively manage patients following tumour resection in breast cancer.
- Trial name
- NCT03696004
- Testing
- FEC-100
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Assiut University
Individualized Chemotherapy
Breast Cancer Treated by Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy, known as "first" or "induction chemotherapy" in the therapeutic assumption of breast cancer is based on the narrow dependence preclinically revealed between primary tumour, tumoral angiogenesis and…
- Trial name
- NCT00425516
- Testing
- Taxotere, 5-Fluorouracil, Epirubicin
- Where
- 6 sites in France
- Volunteers
- 264 people
- Sponsor
- Centre Jean Perrin
Prostate Cancer
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00096304
- Testing
- docetaxel, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Triple Negative Breast Cancer
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as…
- Trial name
- NCT04301739
- Testing
- HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- Volunteers
- 522 people
- Sponsor
- Shanghai Henlius Biotech
Gastric Cancer
Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and tolerability of the ECF regimen (epirubicin, cisplatin and FU) combined with endostar-- a inhibitor of angiogenesis, in patients with advanced or metastatic gastric cancer…
- Trial name
- NCT00595972
- Testing
- ECF-endostar
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Breast Cancer
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
VALENTINE is a parallel, non-comparative, three-arm, randomized 1:2:2 open-label, multicenter, exploratory study in women or men with primary operable HR+/HER2-negative breast cancer with ki67 ≥ 20% and/or high genomic risk…
- Trial name
- VALENTINE (NCT05569811)
- Testing
- Patritumab deruxtecan, Chemotherapy, Letrozole
- Where
- 25 sites in Spain
- Volunteers
- 120 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer, Neutropenia
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00002866
- Testing
- filgrastim, docetaxel, epirubicin hydrochloride
- Where
- 6 sites in Canada
- Volunteers
- 50 people
- Sponsor
- NCIC Clinical Trials Group